Halozyme Therapeutics, Inc. (HALO) Stock: Price, Forecast & Analyst Target
Halozyme Therapeutics, Inc. (HALO) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $91.35 (-1.82%), as of the Nov 20, 2026 trading session; market cap $10.4B. Expected results Feb 16, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 9.68× (cash as of Sep 30, 2026) · expected results Feb 16, 2027
Halozyme Therapeutics, Inc. · HALO · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Halozyme is a drug-delivery platform licensor rather than a conventional developer dependent mainly on medicines it commercializes itself: ENHANZE enables under-the-skin administration of partner therapies, while the company earns royalties, product revenue, bulk-enzyme sales, milestones and collaboration revenue. Durable royalty expansion must carry the story, because leverage is substantial and the economics remain tied to partner medicines using the platform.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Halozyme Therapeutics (HALO)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $354M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 3.48 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $91.35 | |
| Change on the day | -1.82% | |
| 52-week range | $61.23–$134.00 | |
| Market capitalisation | $10.4B | — |
| Price / earnings (trailing) | 22.85 | |
| Shares traded on the day | 1.43M | |
| Beta (volatility vs the S&P 500) | 0.9 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
So we do plan to give 2027 guidance and an update on our long-range outlook when we report fourth quarter results in February.
Darren Snellgrove · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Halozyme Therapeutics (HALO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Halozyme Therapeutics (HALO), and what does it report?
Short answer · as of
The biotechnology label suggests a business funded chiefly by its own therapeutic pipeline.
Research dated 2026-09-13.
Halozyme instead monetizes a patented recombinant human hyaluronidase enzyme across medicines developed and sold by major pharmaceutical partners, alongside Hylenex product sales. Reported revenue therefore combines royalties, products, bulk enzyme, sales-based milestones and collaborative agreements, with royalties forming the largest category.
What do the latest results show for Halozyme Therapeutics (HALO)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $354M.
Research dated 2026-09-13.
The latest reported period produced the strongest revenue, gross profit, operating profit, net income and operating cash flow in the presented quarterly series. Reported revenue and earnings also surpassed expectations after the preceding period had done the same, extending the recovery from the earlier loss and earnings miss.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $492.97M Sep 30, 2026
- Latest quarter · R&D
- $27.78M Sep 30, 2026
- Latest quarter · SG&A
- $58.24M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $294.97M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $492.97M | $27.78M | $58.24M | $294.97M |
| Jun 30, 2026 | $481.00M | $27.66M | $57.00M | $287.65M |
| Mar 31, 2026 | $376.71M | $25.56M | $57.88M | $184.52M |
| Dec 31, 2025 | $451.77M | $31.90M | $77.03M | $240.70M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $492.97M Nov 5, 2026
- Latest report · revenue estimate
- $491.63M Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $492.97M | $491.63M | $2.3900 | $2.3000 |
| Aug 6, 2026 | $481.00M | $402.28M | $2.2800 | $1.7900 |
| May 11, 2026 | $376.71M | $358.60M | $1.6000 | $1.5500 |
| Feb 17, 2026 | $451.77M | $435.71M | −$0.2400 | $2.1500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $354M | $175M | $1.43 (diluted) |
| Q4 FY2025 | $452M | -$142M | -$1.20 (diluted) |
| Q1 FY2026 | $377M | $150M | $1.22 (diluted) |
| Q2 FY2026 | $481M | $230M | $1.90 (diluted) |
What are the financial strengths and risks for Halozyme Therapeutics (HALO)?
Short answer
Cash and short-term investments were $1.07B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $258.27M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Halozyme pairs high gross and operating margins with recurring positive operating cash flow and modest capital spending, giving the platform strong cash-generation characteristics. Liquidity ratios remain comfortable and the quality screens do not signal immediate distress.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $258.27M Sep 30, 2026
- Previous quarter · operating cash flow
- $240.89M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $258.27M | −$3.05M |
| Jun 30, 2026 | $240.89M | −$4.17M |
| Mar 31, 2026 | $180.08M | −$3.74M |
| Dec 31, 2025 | $219.03M | −$1.43M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Halozyme Therapeutics (HALO)?
Short answer · as of
The next earnings report is expected on Feb 16, 2027.
Research dated 2026-09-13.
Royalty revenue is the most informative near-term operating test. Management expects it to keep rising sequentially, but has cautioned that the increase may be less pronounced than the recent step-up. Revenue and earnings against current expectations will show whether that moderation is consistent with continued operating momentum.
What management is planning
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Oct 3, 2025 — 13 months ago.
Checked against the records this page reads, on the dates shown above.
How does Halozyme Therapeutics compare with its peers?
Short answer
Halozyme Therapeutics's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a conventional biotech that must fund and commercialize its own therapies, Halozyme can participate in partner-product sales through ENHANZE royalties. Compared with a typical drug-delivery supplier, its revenue mix reaches beyond product and bulk-enzyme sales into royalties, milestones and collaborations. That structure supports high margins and low capital intensity, but leaves commercial execution largely with pharmaceutical partners while Halozyme retains the economic exposure.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $64.63 Nov 20, 2026 | $15.8B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| Halozyme Therapeutics (HALO) — this page | $91.35 | $10.4B | 95 |
| $156.59 Nov 19, 2026 | $15.9B | 95 5-pillar Nov 18, 2026 | |
| $72.67 Nov 20, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $64.98 Nov 19, 2026 | $7.11B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $124.02 Nov 19, 2026 | $8.09B | 88 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $84.80 Nov 19, 2026 | $9.37B | 73 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $90.00 – $130.00
- Consensus target
- $110.67
- Median target
- $109.50
Consensus record · Captured .
Measured against a quoted price of $91.35 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026
- Transactions
- 57
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 37
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 798 Period end Sep 30, 2026
- Previous quarter · holders
- 693 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 13,668,566 |
| Vanguard Capital Management LLC | 5,106,451 |
| State Street Corp | 5,063,578 |
| Vanguard Portfolio Management LLC | 4,986,956 |
| Jane Street Group, LLC | 3,605,900 |
Tracked investors
Which of the 16 named investors we follow held HALO in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.16% | $36.24M | Trimmed −29.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Halozyme Therapeutics (HALO)?
Common Questions About HALO (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does ENHANZE make money for Halozyme?
Halozyme licenses the delivery platform to pharmaceutical partners and earns through royalties, bulk-enzyme supply, milestones and collaborative agreements as partner programs advance and sell. Royalties are currently the largest reported revenue category.
Why can Halozyme grow without selling every medicine itself?
Partners develop and commercialize medicines that use ENHANZE, allowing Halozyme to participate economically without owning each underlying therapy. Demand therefore depends on partner launches, adoption and commercial performance.
What is Hypercon meant to add to Halozyme?
Management presents Hypercon as a future source of product launches and royalty revenue. Its projected contribution sits well beyond the current reporting horizon, so ENHANZE-linked performance remains the more immediate operating evidence.
Are ENHANZE royalties more important than Hylenex sales?
Royalties are the largest reported revenue category, while all product revenue is reported as a smaller category. Hylenex is Halozyme’s leading proprietary product, but the segment disclosure does not isolate its contribution within product sales.
What is the HALO stock price today?
The last price recorded for Halozyme Therapeutics, Inc. (HALO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the HALO price target?
The analyst consensus price target for Halozyme Therapeutics, Inc. (HALO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 78 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold HALO
Funds in our ETF coverage that list HALO among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| FFLS ETF | 3.26% |